Alaunos director awarded 5,406 shares as board fees

Alaunos Therapeutics, Inc. director Jerman Michael Allen reported receiving 5,406 shares of common stock on 01/12/2026 at $2.89 per share.

Accepted by SEC EDGAR 01/15/2026 - 04:15 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Alaunos Therapeutics, Inc. director Jerman Michael Allen reported receiving 5,406 shares of common stock on 01/12/2026 at $2.89 per share. According to the filing, these shares were issued in lieu of cash board fees, meaning the director took stock as compensation for board service. Following this transaction, he beneficially owns 9,589 shares of Alaunos common stock, held directly.

Insider Trade Summary

Grant/Award: 5,406 shares

Grant/Award 1 txn

Insider Jerman Michael Allen

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,406	$2.89	$16K

Holdings After Transaction: Common Stock — 9,589 shares (Direct)

Footnotes (1)

1. F1. Represents shares of common stock issued in lieu of board fees.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Alaunos Therapeutics (TCRT) report in this Form 4?

The filing reports that director Jerman Michael Allen acquired 5,406 shares of Alaunos Therapeutics, Inc. common stock on 01/12/2026.

At what price were the Alaunos Therapeutics (TCRT) shares acquired in the Form 4?

The 5,406 shares of Alaunos common stock were reported as acquired at a price of $2.89 per share.

Why did the Alaunos Therapeutics director receive 5,406 shares?

A footnote states the 5,406 shares represent common stock issued in lieu of board fees, meaning stock was used instead of cash compensation.

How many Alaunos Therapeutics (TCRT) shares does the reporting person own after this transaction?

After the reported acquisition, Jerman Michael Allen beneficially owns 9,589 shares of Alaunos Therapeutics, Inc. common stock.

Is the Alaunos Therapeutics Form 4 transaction reported as direct or indirect ownership?

The Form 4 indicates the shares are held with direct (D) ownership by the reporting person.

What is the role of the reporting person at Alaunos Therapeutics (TCRT)?

The reporting person, Jerman Michael Allen, is listed as a director of Alaunos Therapeutics, Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jerman Michael Allen

(Last) (First) (Middle)

C/O ALAUNOS THERAPEUTICS, INC.

501 E. LAS OLAS BLVD. SUITE 300

(Street)

FORT LAUDERDALE FL 33301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alaunos Therapeutics, Inc. [ TCRT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/12/2026		A		5,406(1)	A	$2.89	9,589	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock issued in lieu of board fees.

	/s/ Michael, Jerman A	01/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.